ArsenalBio
Arsenal Biosciences is a clinical-stage cell therapy company developing treatments for solid tumors using CRISPR and logic-gated CAR-T therapies.
Secondary Market Price
How ArsenalBio Measures Up
To help you manage your ArsenalBio equity, Prospect has run the company through our machine learning model.
Prospect Rating
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of ArsenalBio's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future ArsenalBio Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for ArsenalBio's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Arsenal Biosciences is a clinical-stage programmable cell therapy company developing treatments for solid tumors. The company's current work centers on advancing autologous CAR-T cell therapies, with a lead program targeting metastatic prostate cancer. To achieve this, ArsenalBio utilizes a discovery engine that includes CRISPR-enabled genome editing, integrated circuits with logic gates for tumor targeting, and other therapeutic enhancements. Founded in 2019 and headquartered in South San Francisco, CA, the company has grown to between 201-500 employees and specializes in biotechnology, immunology, and machine learning applications for cell therapy.
Looking forward, ArsenalBio is advancing its primary autologous CAR-T cell therapy candidate for metastatic prostate cancer toward clinical studies. The company continues to present its research at industry conferences, with recent poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting that highlighted its lead candidate and a foundation model for overcoming T-cell exhaustion. Other recent developments include a $325M Series C funding round and the recognition of Co-founder and CEO Ken Drazan as a winner in the EY Entrepreneur Of The Year 2025 Bay Area program.
- ARCH Venture Partners
- Milky Way Investments Group
- Regeneron Ventures
- NVentures
- Luma Group
- T. Rowe Price Associates
- Rock Springs Capital
- Parker Institute for Cancer Immunotherapy
- SoftBank Vision Fund 2
- Bristol-Myers Squibb Company
- Westlake Village BioPartners
- Kleiner Perkins
- Byers Capital
- Hitachi Ventures
- Co-Founder, Ken Drazan
- Co-Founder, W. Nicholas Haining
- Co-Founder, Kole Roybal
- Co-Founder, Brad Bernstein
- Co-Founder, Alexander Marson
- Co-Founder, E. John Wherry
- Co-Founder, Theo Roth
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is ArsenalBio worth joining?
Deciding whether to join a company like ArsenalBio depends on your personal career goals and financial situation. Tools like Prospect can help you model the potential future value of your equity compensation to make a more informed decision.
What should I do with my ArsenalBio stock?
Managing your ArsenalBio equity involves creating a strategy for when to exercise options and how to plan for taxes. Platforms like Prospect offer personalized, tax-optimized strategies to help you maximize the value of your shares.
Can you sell ArsenalBio stock?
As a private company, selling ArsenalBio stock is typically possible through company-approved tender offers or on secondary markets. Prospect provides tender offer tools to help you decide how much to sell and which shares are most tax-optimal.
How can I find the value of my ArsenalBio stock?
The value of private stock like ArsenalBio's is often determined by its latest 409A valuation and prices on secondary markets. To get a more forward-looking estimate, Prospect uses proprietary predictive models to project the future value of your shares.
What is ArsenalBio's equity worth?
The worth of your ArsenalBio equity isn't a single number but a range of potential outcomes that depends on the company's future success. You can use financial modeling tools like those offered by Prospect to forecast different scenarios and understand the potential value.
What is ArsenalBio's stock ticker symbol?
ArsenalBio is a private company, so it does not have a stock ticker symbol. Ticker symbols are assigned to companies only when they become publicly traded on a stock exchange.
Can I buy or sell ArsenalBio stock?
Selling private ArsenalBio stock is sometimes possible during tender offers or on secondary markets, while buying shares is typically restricted to accredited investors and institutional funds. Prospect offers tools to help employees navigate sales opportunities like tender offers when they arise.
What is the criteria to buy or invest in ArsenalBio stock?
Investing in a private company like ArsenalBio is usually limited to accredited investors, who meet specific income or net worth thresholds defined by regulators. Employees, however, receive equity as part of their compensation without needing to meet these criteria.
